EpiCast Report: Diabetic Nephropathy - Epidemiology Forecast to 2022

With the increasing prevalence of diabetes around the world, diabetic nephropathy is the most common type of chronic kidney disease (KDOQI, 2007; Zimmet et al., 2001). When uncontrolled diabetes persists for 15 to 25 years, the blood vessels in the kidneys are damaged, resulting in abnormal amounts of proteins, including albumin, leaking into the urine (ADA, 2013; CDA, 2012; NHS, 2011; NKUDIC, 2013). Because diabetic nephropathy is a complication of diabetes, and at least 90% of all diabetic cases are type 2 diabetes, the risk factors and common comorbidities for type 2 diabetes are also considered to be the same for diabetic nephropathy. The major risk factors for type 2 diabetes are family history, advancing age, obesity, and gestational diabetes. Hypertension and dyslipidemia are also the most commonly-occurring comorbidities in people with diabetic nephropathy (GlobalData, 2013b).

According to GlobalData’s forecast, the 7MM had 4,889,171 prevalent cases of diabetic retinopathy in 2012. There were 14.03 million total prevalent cases of diabetic nephropathy in the diagnosed diabetic population in the 7MM, there will be 19.87 million total prevalent cases of diabetic nephropathy in the diagnosed diabetic population in the 7MM by 2022, with an annual growth rate (AGR) of 4.16% during the forecast period.

Scope

The diabetic nephropathy EpiCast Report provides an overview of the risk factors and epidemiological trends for diabetic nephropathyin the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the total prevalent cases of diabetic retinopathy in the diagnosed diabetic population segmented by age, (over 40 years of age) and sex. The diagnosed prevalent cases are then further segmented by the presence of comorbid hypertension. The diabetic nephropathy epidemiology report was written and developed by Masters- and PhD-level epidemiologists. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

Develop business strategies by understanding the trends shaping and driving the global diabetic nephropathy market.

Quantify patient populations in the global diabetic nephropathy market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for diabetic nephropathy therapeutics in each of the markets covered.

Table of Contents

1Table of Contents1

1.1List of Tables2

1.2List of Figures3

2Executive Summary3

3Introduction5

3.1Catalyst5

3.2Related Reports6

3.3Upcoming Reports6

4Epidemiology6

4.1Disease ...

1Table of Contents1

1.1List of Tables2

1.2List of Figures3

2Executive Summary3

3Introduction5

3.1Catalyst5

3.2Related Reports6

3.3Upcoming Reports6

4Epidemiology6

4.1Disease Background6

4.2Risk Factors and Comorbidities8

4.2.1Poor glycemic control elevates the risk of diabetic nephropathy8

4.3Global Trends9

4.3.1US9

4.3.25EU10

4.3.3Japan10

4.4Epidemiological Forecast for Diabetic Nephropathy (2012–2022)11

4.4.1Forecast Methodology11

4.4.2Sources Used11

4.4.3Sources Not Used13

4.5Epidemiological Forecast for Diabetic Nephropathy (2012–2022)14

4.5.1Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Diabetes14

4.5.2Forecast Assumptions and Methods — Diabetic Nephropathy18

4.6Epidemiology Forecast for Diabetic Nephropathy (2012–2022)20

4.6.1Total Prevalent Cases of Diabetic Nephropathy20

4.6.2Total Prevalent Cases of Diabetic Nephropathy by Age22

4.6.3Total Prevalent Cases of Diabetic Nephropathy by Sex23

4.6.4Total Prevalent Cases of Comorbid Hypertension in Total Diabetic Nephropathy25

4.7Discussion25

4.7.1Epidemiological Forecast Insight25

4.7.2Limitations of the Analysis27

4.7.3Strengths of the Analysis28

5Appendix28

5.1Bibliography28

5.2About the Authors32

5.2.1Epidemiologists32

5.2.2Reviewers32

5.2.3Global Director of Epidemiology and Health Policy33

5.2.4Global Head of Healthcare33

5.3About GlobalData35

5.4About EpiCast35

5.5Contact Us35

5.6Disclaimer36

List of Tables

Table 1: Classification of Patients Based on the Levels of Albuminuria for the Three Standard Tests7

Table 2: 7MM, Sources of the Total Prevalence Data ...

Table 1: Classification of Patients Based on the Levels of Albuminuria for the Three Standard Tests7

Table 2: 7MM, Sources of the Total Prevalence Data Used in the Analysis of Diabetic Nephropathy11

Table 3: 7MM, Sources Excluded from the Analysis of Diabetic Nephropathy13

Table 4: 7MM, Total Prevalent Cases of Diabetic Nephropathy in the Diagnosed Diabetic Population, Both Sexes, Ages =40 Years, N, 2012–202220

Table 5: 7MM, Total Prevalent Cases of Diabetic Nephropathy in the Diagnosed Diabetic Population, Both Sexes, by Age, N, Row (%), 201222

Table 6: 7MM, Total Prevalent Cases of Diabetic Nephropathy in the Diagnosed Diabetic Population, by Sex, Ages =40, N, Row (%), 201224

List of Figures

Figure 1: 7MM, Total Prevalent Cases of Diabetic Nephropathy in the Diagnosed Diabetic Population, Both Sexes, N, 2012 and 20224

Figure 2: 7MM, Total Prevalent ...

Figure 1: 7MM, Total Prevalent Cases of Diabetic Nephropathy in the Diagnosed Diabetic Population, Both Sexes, N, 2012 and 20224

Figure 2: 7MM, Total Prevalent Cases of Diabetic Nephropathy in the Diagnosed Diabetic Population, Both Sexes, Ages =40 Years, N, 2012–202221

Figure 3: 7MM, Total Prevalent Cases of Diabetic Nephropathy in the Diagnosed Diabetic Population, Both Sexes, by Age, N, 201223

Figure 4: 7MM, Total Prevalent Cases of Diabetic Nephropathy in the Diagnosed Diabetic Population, by Sex, Ages =40 Years, N, 201224

Figure 5: 7MM, Total Prevalent Cases of Comorbid Hypertension in Total Prevalent Cases of Diabetic Nephropathy, Both Sexes, Ages =40 Years, N, 201225

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Saved reports